Proteogenomics and clinical translation

Synopsis

Proteogenomics melds the complexity of cancer genomics with cancer proteomics to more completely understand how somatic genomes activate aberrant signal transduction events that drive cancer pathogenesis. We postulate that this integrated approach will provide new understanding of the biology of response and resistance to chemotherapeutics, sounder therapeutic hypotheses and identify more accurate predictive biomarkers for drug resistance and treatment selection that could be developed and deployed as clinical tests.